Intellia Therapeutics (NTLA) to Release Quarterly Earnings on Thursday

Intellia Therapeutics (NASDAQ:NTLA) is projected to announce its earnings results before the market opens on Thursday, February 27th. Analysts expect the company to announce earnings of ($1.32) per share and revenue of $8.10 million for the quarter. Investors that are interested in registering for the company’s conference call can do so using this link.

Intellia Therapeutics Stock Down 7.0 %

Shares of NTLA stock opened at $10.71 on Wednesday. Intellia Therapeutics has a 12 month low of $8.96 and a 12 month high of $34.87. The company’s fifty day simple moving average is $10.99 and its 200-day simple moving average is $15.87. The firm has a market cap of $1.09 billion, a PE ratio of -1.97 and a beta of 1.80.

Insider Activity at Intellia Therapeutics

In other Intellia Therapeutics news, CEO John M. Leonard sold 26,807 shares of the stock in a transaction dated Friday, January 3rd. The stock was sold at an average price of $12.18, for a total transaction of $326,509.26. Following the completion of the sale, the chief executive officer now directly owns 941,115 shares in the company, valued at approximately $11,462,780.70. This trade represents a 2.77 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders have sold 29,000 shares of company stock worth $352,551 over the last ninety days. Insiders own 3.20% of the company’s stock.

Analyst Upgrades and Downgrades

NTLA has been the topic of several research reports. Oppenheimer decreased their price objective on shares of Intellia Therapeutics from $60.00 to $40.00 and set an “outperform” rating on the stock in a report on Monday, January 13th. Morgan Stanley downgraded shares of Intellia Therapeutics from an “overweight” rating to an “equal weight” rating and decreased their price target for the company from $56.00 to $11.00 in a research note on Monday, January 27th. Wells Fargo & Company dropped their price objective on shares of Intellia Therapeutics from $70.00 to $60.00 and set an “overweight” rating for the company in a research note on Friday, January 10th. The Goldman Sachs Group dropped their price target on Intellia Therapeutics from $19.00 to $12.00 and set a “neutral” rating for the company in a research note on Tuesday, January 14th. Finally, Wedbush reissued a “neutral” rating and issued a $10.00 price objective (down from $14.00) on shares of Intellia Therapeutics in a research note on Friday, January 10th. One research analyst has rated the stock with a sell rating, six have given a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $48.71.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.